Atomoxetine

• CAT Number: I022619
• CAS Number: 83015-26-3
• Molecular Formula: C17H21NO
• Molecular Weight: 255.36
• Purity: 98%
• Synonyms: Atomoxetine; HSDB 7352; HSDB-7352; HSDB7352
• Target: Membrane Transporter/Ion Channel
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
• IUPAC Name: Benzenepropanamine, N-methyl-gamma-(2-methylphenoxy)-, (gammaR)-
• InChI: InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
• InChIKey: VHGCDTVCOLNTBX-QGZVFWFLSA-N
• SMILES: CC1=CC=CC=C1O[C@@H](C2=CC=CC=C2)CCNC

Atomoxetine (Cat.No:I022619) is a selective inhibitor of noradrenaline reuptake; atomoxetine was originally called tomoxetine but changed to avoid any potential confusion with tamoxifen that might lead to errors in dispensing the drug.

Reference

1: Mosholder AD, Taylor L, Mannheim G, Ortendahl L, Woodworth TS, Toh S. Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study. J Clin Psychopharmacol. 2018 Aug 10. doi: 10.1097/JCP.0000000000000939. [Epub ahead of print] PubMed PMID: 30102629.
2: Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Aug 7. pii: S2215-0366(18)30269-4. doi: 10.1016/S2215-0366(18)30269-4. [Epub ahead of print] PubMed PMID: 30097390.
3: Froehlich T, Fogler J, Barbaresi WJ, Elsayed NA, Evans SW, Chan E. Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review. Clin Pharmacol Ther. 2018 Jul 27. doi: 10.1002/cpt.1192. [Epub ahead of print] Review. PubMed PMID: 30053315.
4: van den Brink RL, Nieuwenhuis S, Donner TH. Amplification and Suppression of Distinct Brain-wide Activity Patterns by Catecholamines. J Neurosci. 2018 Jul 23. pii: 0514-18. doi: 10.1523/JNEUROSCI.0514-18.2018. [Epub ahead of print] PubMed PMID: 30037827.
5: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501732/ PubMed PMID: 30000791.
6: Biaggioni I. Orthostatic Hypotension in the Hypertensive Patient. Am J Hypertens. 2018 Jul 2. doi: 10.1093/ajh/hpy089. [Epub ahead of print] PubMed PMID: 29982276.
7: Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018 Jun 26;6:CD007990. doi: 10.1002/14651858.CD007990.pub3. Review. PubMed PMID: 29944175.
8: Kweon K, Yoon JS, Park KJ, Kim SO, Choi JH, Kim HW. Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review. Psychiatry Investig. 2018 Jun;15(6):649-654. doi: 10.30773/pi.2018.02.25.1. Epub 2018 Jun 21. PubMed PMID: 29940719; PubMed Central PMCID: PMC6018137.
9: Edvinsson D, Ekselius L. Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A 6-Year Prospective Naturalistic Study. J Clin Psychopharmacol. 2018 Aug;38(4):370-375. doi: 10.1097/JCP.0000000000000917. PubMed PMID: 29927781; PubMed Central PMCID: PMC6039396.
10: Naguy A, Alamiri B, El-Sori DS, Khraibut B. Methylphenidate-Associated Onychotillomania, Myoclonus, and Enuresis Reversed by Switching to Atomoxetine. Am J Ther. 2018 Jun 18. doi: 10.1097/MJT.0000000000000812. [Epub ahead of print] PubMed PMID: 29927775.
11: Yonezawa K, Nonaka S, Iwakura Y, Kusano Y, Funamoto Y, Kanchi N, Yamaguchi N, Kusumoto Y, Imamura A, Ozawa H. Investigation into the plasma concentration of ω3 polyunsaturated fatty acids in Japanese attention-deficit hyperactivity disorder patients. J Neural Transm (Vienna). 2018 Jun 20. doi: 10.1007/s00702-018-1895-z. [Epub ahead of print] PubMed PMID: 29926268.
12: Frampton JE. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD. Drugs. 2018 Jul;78(10):1025-1036. doi: 10.1007/s40265-018-0936-0. PubMed PMID: 29923015.
13: Moreira-Maia CR, Massuti R, Tessari L, Campani F, Akutagava-Martins GC, Cortese S, Rohde LA. Are ADHD medications under or over prescribed worldwide?: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2018 Jun;97(24):e10923. doi: 10.1097/MD.0000000000010923. Review. PubMed PMID: 29901582; PubMed Central PMCID: PMC6023876.
14: Pozzi M, Carnovale C, Peeters GGAM, Gentili M, Antoniazzi S, Radice S, Clementi E, Nobile M. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: A meta-analysis. J Affect Disord. 2018 Oct 1;238:161-178. doi: 10.1016/j.jad.2018.05.021. Epub 2018 May 22. Review. PubMed PMID: 29883938.
15: Coppola M, Mondola R. Impulsivity in Alcohol-Dependent Patients with and without ADHD: The Role of Atomoxetine. J Psychoactive Drugs. 2018 Jun 7:1-6. doi: 10.1080/02791072.2018.1471247. [Epub ahead of print] PubMed PMID: 29877779.
16: Okumura Y, Usami M, Okada T, Saito T, Negoro H, Tsujii N, Fujita J, Iida J. Prevalence, incidence and persistence of ADHD drug use in Japan. Epidemiol Psychiatr Sci. 2018 May 28:1-5. doi: 10.1017/S2045796018000252. [Epub ahead of print] PubMed PMID: 29804548.
17: Naguy A, Alamiri B, Khraibut B. Weight Loss During Atomoxetine Add-on to Clozapine-Responsive Schizophrenia. Am J Ther. 2018 May 16. doi: 10.1097/MJT.0000000000000785. [Epub ahead of print] PubMed PMID: 29782344.
18: Ghorbani M, Chamsaz M, Aghamohammadhasan M, Shams A. Ultrasonic assisted magnetic dispersive solid phase microextraction for pre concentration of serotonin-norepinephrine reuptake inhibitor drugs. Anal Biochem. 2018 Jun 15;551:7-18. doi: 10.1016/j.ab.2018.05.003. Epub 2018 May 8. PubMed PMID: 29750941.
19: Arnold LE, Ober N, Aman MG, Handen B, Smith T, Pan X, Hyman SL, Hollway J, Lecavalier L, Page K, Rice R Jr. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):322-330. doi: 10.1089/cap.2017.0134. Epub 2018 Apr 25. PubMed PMID: 29694241; PubMed Central PMCID: PMC5994674.
20: Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018 Feb;30(1):78-95. doi: 10.1080/09540261.2018.1458706. Epub 2018 Apr 25. PubMed PMID: 29693461.